Another UK Biotech Snapped Up As Neurocrine Buys Diurnal
US Firm Paying Just £48m
Lack of scale, the need for further funding and problems getting reimbursement for its adrenal insufficiency products left the Wales-headquartered firm vulnerable to a takeover and San Diego's Neurocrine has swooped.
You may also be interested in...
Arcutis Eyes Atopic Dermatitis Opportunity With Ducentis Buy
Arcutis's CEO believes that with "a modest investment," the company can generate proof-of-concept data "against a de-risked target in a high-value indication,” Ducentis's preclinical atopic dermatits drug DS-234.
Deal Watch: Roche, PhoreMost Enter Into Multi-Target Collaboration
Plus deals with Synaffix/Emergence, Helsinn/Juniper and Sanyou/Shanghai KangaBio, while Takeda/Finch and Dong-A/Beactica ended prior collaborations.
Gilead Grabs MiroBio's Checkpoint Agonists For $405m
Just over a month after raising $97m in a series B round, Oxford University spinout MiroBio and its immune checkpoint agonists have been snapped up by Gilead Sciences.